Kestra Medical Technologies Ltd.
07/14/2026 | Press release | Distributed by Public on 07/14/2026 14:09
Kestra Medical Technologies Reports Fourth Quarter and Fiscal Year 2026 Financial Results (Form 8-K)
Kestra Medical Technologies Reports Fourth Quarter and Fiscal Year 2026 Financial Results
KIRKLAND, Wash., July 14, 2026 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (Nasdaq: KMTS), a leading wearable medical device and digital healthcare company, today reported financial results for the fourth quarter and fiscal year ended April 30, 2026.
Financial Highlights
•
Fiscal 4Q26 revenue of $28.6 million, an increase of 66% compared to the prior year period.
•
FY26 revenue of $95.1 million, an increase of 59% compared to FY25.
•
Fiscal 4Q26 gross margin of 54.8% compared to 44.3% in the prior year period.
•
FY26 gross margin of 51.4% compared to 40.5% in FY25.
•
FY27 revenue guidance of $137 million, an increase of 44% compared to fiscal year 2026.
"Kestra concluded fiscal year 2026 with another strong quarter of financial performance, generating revenue growth of 66% while expanding gross margin to 55%," said Brian Webster, President and CEO. "In fiscal year 2026, the ASSURE® system protected 18,000 patients from sudden cardiac arrest, a testament to the dedication of our mission-driven team. We also made significant progress on key operational objectives, including rapid growth of our commercial organization, release of compelling primary results from our FDA post-approval study, launch of our latest algorithm update, fortification of our balance sheet, and entrance into a strategic collaboration with Biobeat Technologies. We remain confident that our focus on innovation and executing on our commitments to prescribers and their patients will continue to drive market expansion and advance Kestra on its path to market leadership."
Fourth Quarter Fiscal 2026 Financial Results
•
Total revenue was $28.6 million, an increase of 66% compared to the prior year period.
o
6,357 prescriptions were written for the ASSURE® system, an increase of 63% compared to the prior year period.
o
Revenue growth was driven primarily by higher market share and wearable cardioverter defibrillator (WCD) market expansion. Revenue also benefited from a higher mix of in-network patients and improvements in revenue cycle management capabilities.
•
Gross profit was $15.7 million compared to $7.6 million in the prior year period.
o
Gross margin expanded to 54.8% compared to 44.3% in the prior year period, driven by volume leverage, a higher mix of in-network patients and execution of planned cost improvement programs.
•
GAAP operating expenses were $55.0 million compared to $55.8 million in the prior year period.
o
Excluding non-recurring costs and share-based compensation expense, adjusted operating expenses* were $44.7 million compared to $29.7 million in the prior year period. The increase was primarily attributable to growth in expenses related to the company's accelerated commercial expansion.
•
GAAP net loss was $38.8 million compared to GAAP net loss of $51.1 million in the prior year period.
o
Adjusted EBITDA* loss was $26.7 million compared to an adjusted EBITDA loss of $20.3 million in the prior year period.
•
Cash and cash equivalents, and investments totaled $262.2 million as of April 30, 2026.
o
Net cash used in operating activities was $18.7 million, a reduction from $24.1 million in the prior year period.
Fiscal Year 2026 Financial Results
•
Total revenue was $95.1 million, an increase of 59% compared to FY25.
o
20,720 prescriptions were written for the ASSURE® system, an increase of 57% compared to FY25.
•
Gross profit was $48.9 million compared to $24.2 million in FY25.
o
Gross margin expanded to 51.4% compared to 40.5% in FY25.
•
GAAP operating expenses were $183.6 million compared to $130.6 million in FY25.
o
Excluding non-recurring costs and share-based compensation expense, adjusted operating expenses* were $144.6 million compared to $100.6 million in FY25.
•
GAAP net loss was $131.6 million compared to GAAP net loss of $113.8 million in FY25.
o
Adjusted EBITDA* loss was $87.0 million compared to an adjusted EBITDA loss of $68.4 million in FY25.
*Adjusted operating expenses and adjusted EBITDA are non-GAAP financial measures. See "Use of Non-GAAP Financial Measures" below for additional information. Reconciliations of adjusted operating expenses and adjusted EBITDA to the most directly comparable GAAP measure are included in this press release.
Fiscal Year 2027 Revenue Guidance
Kestra expects revenue of $137 million in FY27, which would represent growth of 44% compared to FY26.
Webcast and Conference Call
Kestra will host a conference call today at 4:30 p.m. Eastern Time to discuss financial results. A live and archived webcast of the event will be available in the "Events" section of the investor relations website.
About Kestra
Kestra Medical Technologies, Ltd. is a leading wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. For more information, visit www.kestramedical.com.
Use of Non-GAAP Financial Measures
Kestra Medical Technologies Ltd. published this content on July 14, 2026, and is solely responsible for the information contained herein. Distributed via EDGAR on July 14, 2026 at 20:09 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]